Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2023-06-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
新疆驿讯商贸有限公司审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed auditor opinions, responsibilities, and audit scope statements consistent with an audit report. It includes financial statements such as balance sheets and income statements for specific dates (2022 year-end and 2023 Q1). The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes auditor signatures and detailed financial data, confirming it is the actual audit report, not just an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). Q1 2023
2023-06-21 Chinese
第五届监事会第二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed at the second meeting of the fifth Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It details the approval of a proposal to sell 51% equity of two subsidiaries. The document includes voting results and states that the proposal will be submitted to a shareholders' meeting. It is a formal announcement of a board/management decision regarding company asset restructuring and shareholding changes. It is not a full financial report, audit, or earnings release, nor is it a proxy or AGM material. The content fits best under Board/Management Information (MANG) as it announces a board resolution and management decision.
2023-06-21 Chinese
第五届董事会第二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the company's fifth board of directors' second meeting. It includes decisions on the sale of controlling stakes in subsidiaries, appointment of company vice presidents, and the scheduling of a shareholders' meeting. The content focuses on board decisions and management appointments rather than financial results or detailed reports. The document length is 2387 characters, which is relatively short and typical for a board meeting resolution announcement. There is no detailed financial data or comprehensive report content. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces changes in senior management and board decisions.
2023-06-21 Chinese
瑞康医药独立董事对第五届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 瑞康医药集团股份有限公司 regarding matters discussed at the company's fifth board of directors second meeting. It includes opinions on asset sales and appointment of vice presidents, referencing compliance with company law, stock exchange rules, and company articles. The document is a formal board/management related announcement, specifically about board meeting matters and management appointments. It does not contain financial statements or detailed financial data, nor is it a full annual or interim report. It is not a regulatory filing or announcement of a report publication. Therefore, the document fits best under Board/Management Information (MANG). The document length is short (1040 characters), consistent with a management announcement rather than a full report.
2023-06-21 Chinese
关于出售资产的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the sale of assets by 瑞康医药集团股份有限公司 (Ruikang Medical Group Co., Ltd.). It includes information about the transaction parties, approval procedures, financial data of the assets being sold, pricing basis, and the impact on the company. It references audit reports for the assets involved but does not itself contain a full audit report or financial statements for the company as a whole. The document is a formal announcement of a significant asset sale transaction requiring shareholder approval, consistent with a capital or financing update. It is not an annual report, interim report, earnings release, or any other report type. The document length (6459 characters) and content indicate it is a full announcement rather than a brief notice or a report publication announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-06-21 Chinese
关于指定董事代行董事会秘书职责的公告
Board/Management Information Classification · 100% confidence The document is an announcement from 瑞康医药集团股份有限公司 regarding the appointment of a director to act as the board secretary following a board re-election. It details the resignation of the previous board secretary and the temporary appointment of a new director to fulfill the board secretary duties. The document includes contact information and compliance statements but does not contain financial data, audit information, or detailed management reports. It is clearly an announcement about board/management changes rather than a financial report or other filing type. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a report publication or regulatory filing.
2023-05-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.